Literature DB >> 6816064

Inhibition of nocturnal gastric secretion in normal human volunteers by misoprostol: a synthetic prostaglandin E1 methyl ester analog.

K Akdamar, N Agrawal, A Ertan.   

Abstract

Misoprostol (SC-29333) is a synthetic prostaglandin E1 analog that has been found to be a potent inhibitor of gastric secretion in animals. Nocturnal gastric antisecretory activity of misoprostol, in tablet form, was studied in 16 adult volunteers, under basal condition. The study was a randomized, double-blind, cross-over, comparison of placebo, and three graded doses of misoprostol (50, 100, and 200 micrograms). Misoprostol exhibited a statistically significant inhibition of total acid output only at the 200 micrograms dose and this inhibition was maintained for 3 h postadministration of the drug. The antisecretory effects of misoprostol were characterized by suppression of H+ ion but not of the volume of gastric secretion. No untoward effects were noted in the volunteers. As a consequence of the gastric antisecretory effects, the present studies indicate that misoprostol is a promising therapeutic agent for the treatment of peptic ulcer.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6816064

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Effect of rioprostil, a methylprostaglandin E1 analog, on basal and stimulated plasma pancreatic hormone levels in man.

Authors:  O Segers; G Somers
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

2.  Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer.

Authors:  J E McGuigan; Y Chang; E Z Dajani
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

Review 3.  Overview of misoprostol clinical experience.

Authors:  R L Herting; C H Nissen
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

4.  Gastric protection by misoprostol against 1300 mg of aspirin. An endoscopic study.

Authors:  F E Silverstein; M B Kimmey; D R Saunders; D S Levine
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

5.  Evaluation of antisecretory activity of misoprostol in duodenal ulcer patients using long-term intragastric pH monitoring.

Authors:  V Savarino; P Scalabrini; G S Mela; E di Timoteo; G Percario; M R Magnolia; G Celle
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

6.  Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor-alpha.

Authors:  M Mahatma; N Agrawal; E Z Dajani; S Nelson; C Nakamura; J Sitton
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

7.  A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease.

Authors:  C K Ching; S K Lam
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

8.  Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man.

Authors:  M M Cohen; L Clark; L Armstrong; J D'Souza
Journal:  Dig Dis Sci       Date:  1985-07       Impact factor: 3.199

9.  Misoprostol clinical pharmacology. Establishment of activity in man.

Authors:  J A Steiner
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

10.  Misoprostol, a synthetic PGE1 analog, in the treatment of duodenal ulcers. A multicenter double-blind study.

Authors:  D L Brand; W M Roufail; A B Thomson; E J Tapper
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.